GSE111061 tofacitinib 1 v 3 human dn (Gene Set)

Analyze

Playbook Workflow Builder
Playbook Workflow Builder: Gene Set Enrichment

Perform Gene Set Enrichment with this gene set against Common Fund program's gene sets, identifying significant overlaps using a pre-built PWB workflow. Run the workflow with GSE111061_tofacitinib_1_v_3_human_dn.

GeneSetCart
GeneSetCart

GeneSetCart helps you to fetch gene sets from various data sources, augment, combine with set operations, visualize and analyze these gene sets in a single session. Start a new session with GSE111061_tofacitinib_1_v_3_human_dn.

CFDE-GSE
CFDE Gene Set Enrichment (GSE)

CFDE-GSE illuminates connections between the input gene set and various CF gene sets that overlap with the queried gene set. Query CFDE-GSE with GSE111061_tofacitinib_1_v_3_human_dn.

Playbook Workflow Builder
Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with GSE111061_tofacitinib_1_v_3_human_dn.

Results found

Linked to

 

Label

Description

 

Gene

ASNSD1 upstream open reading frame

Gene

tripartite motif containing 10

Gene

uncharacterized LOC389602

Gene

cytoskeleton associated protein 2-like pseudogene

Gene

G-quadruplex forming sequence containing lncRNA

Gene

keratin 16 pseudogene 3

Gene

BTG3 antisense RNA 1

Gene

uncharacterized LOC100128770

Gene

RASAL2 antisense RNA 1

Gene

THBS4 antisense RNA 1

  • Gene

    ASNSD1 upstream open reading frame


  • Gene

    tripartite motif containing 10


  • Gene

    uncharacterized LOC389602


  • Gene

    cytoskeleton associated protein 2-like pseudogene


  • Gene

    G-quadruplex forming sequence containing lncRNA


  • Gene

    keratin 16 pseudogene 3


  • Gene

    BTG3 antisense RNA 1


  • Gene

    uncharacterized LOC100128770


  • Gene

    RASAL2 antisense RNA 1


  • Gene

    THBS4 antisense RNA 1

  • DISPLAY PER PAGE
    This repository is under review for potential modification in compliance with Administration directives.